314 related articles for article (PubMed ID: 14967373)
1. Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin.
Maciel GA; Soares Júnior JM; Alves da Motta EL; Abi Haidar M; de Lima GR; Baracat EC
Fertil Steril; 2004 Feb; 81(2):355-60. PubMed ID: 14967373
[TBL] [Abstract][Full Text] [Related]
2. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity.
Baillargeon JP; Jakubowicz DJ; Iuorno MJ; Jakubowicz S; Nestler JE
Fertil Steril; 2004 Oct; 82(4):893-902. PubMed ID: 15482765
[TBL] [Abstract][Full Text] [Related]
3. Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial.
Chou KH; von Eye Corleta H; Capp E; Spritzer PM
Horm Metab Res; 2003 Feb; 35(2):86-91. PubMed ID: 12734787
[TBL] [Abstract][Full Text] [Related]
4. Two weeks of metformin improves clomiphene citrate-induced ovulation and metabolic profiles in women with polycystic ovary syndrome.
Khorram O; Helliwell JP; Katz S; Bonpane CM; Jaramillo L
Fertil Steril; 2006 May; 85(5):1448-51. PubMed ID: 16579997
[TBL] [Abstract][Full Text] [Related]
5. The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome.
Yilmaz M; Bukan N; Ayvaz G; Karakoç A; Törüner F; Cakir N; Arslan M
Hum Reprod; 2005 Dec; 20(12):3333-40. PubMed ID: 16123091
[TBL] [Abstract][Full Text] [Related]
6. Predictive value of glucose-insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic?
Onalan G; Goktolga U; Ceyhan T; Bagis T; Onalan R; Pabuçcu R
Eur J Obstet Gynecol Reprod Biol; 2005 Dec; 123(2):204-11. PubMed ID: 16316811
[TBL] [Abstract][Full Text] [Related]
7. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
Panidis D; Farmakiotis D; Rousso D; Kourtis A; Katsikis I; Krassas G
Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364
[TBL] [Abstract][Full Text] [Related]
8. Effect of metformin on serum visfatin levels in patients with polycystic ovary syndrome.
Ozkaya M; Cakal E; Ustun Y; Engin-Ustun Y
Fertil Steril; 2010 Feb; 93(3):880-4. PubMed ID: 19111298
[TBL] [Abstract][Full Text] [Related]
9. Metformin therapy increases insulin-like growth factor binding protein-1 in hyperinsulinemic women with polycystic ovary syndrome.
Pawelczyk L; Spaczynski RZ; Banaszewska B; Duleba AJ
Eur J Obstet Gynecol Reprod Biol; 2004 Apr; 113(2):209-13. PubMed ID: 15063962
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial.
Trolle B; Flyvbjerg A; Kesmodel U; Lauszus FF
Hum Reprod; 2007 Nov; 22(11):2967-73. PubMed ID: 17766923
[TBL] [Abstract][Full Text] [Related]
11. Effects of metformin on clinical and biochemical parameters in polycystic ovary syndrome.
Kriplani A; Agarwal N
J Reprod Med; 2004 May; 49(5):361-7. PubMed ID: 15214709
[TBL] [Abstract][Full Text] [Related]
12. The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome.
Yilmaz M; Karakoç A; Törüner FB; Cakir N; Tiras B; Ayvaz G; Arslan M
Gynecol Endocrinol; 2005 Sep; 21(3):154-60. PubMed ID: 16335907
[TBL] [Abstract][Full Text] [Related]
13. Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome.
Fruzzetti F; Perini D; Lazzarini V; Parrini D; Gambacciani M; Genazzani AR
Fertil Steril; 2010 Oct; 94(5):1793-8. PubMed ID: 19931080
[TBL] [Abstract][Full Text] [Related]
14. A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study.
Hoeger KM; Kochman L; Wixom N; Craig K; Miller RK; Guzick DS
Fertil Steril; 2004 Aug; 82(2):421-9. PubMed ID: 15302293
[TBL] [Abstract][Full Text] [Related]
15. Effects of metformin treatment in women with polycystic ovary syndrome depends on insulin resistance.
Nawrocka J; Starczewski A
Gynecol Endocrinol; 2007 Apr; 23(4):231-7. PubMed ID: 17505944
[TBL] [Abstract][Full Text] [Related]
16. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
Pasquali R; Gambineri A; Biscotti D; Vicennati V; Gagliardi L; Colitta D; Fiorini S; Cognigni GE; Filicori M; Morselli-Labate AM
J Clin Endocrinol Metab; 2000 Aug; 85(8):2767-74. PubMed ID: 10946879
[TBL] [Abstract][Full Text] [Related]
17. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
Wu J; Zhu Y; Jiang Y; Cao Y
Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
[TBL] [Abstract][Full Text] [Related]
18. Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome.
Mitkov M; Pehlivanov B; Terzieva D
Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):93-8. PubMed ID: 16360262
[TBL] [Abstract][Full Text] [Related]
19. Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome.
Ortega-González C; Cardoza L; Coutiño B; Hidalgo R; Arteaga-Troncoso G; Parra A
J Endocrinol; 2005 Jan; 184(1):233-9. PubMed ID: 15642799
[TBL] [Abstract][Full Text] [Related]
20. [Role of hyperinsulinemia in pathogenesis of polycystic ovary syndrome and treatment by reduction of insulin secretion].
Wang A; Li M; Lu C
Zhonghua Fu Chan Ke Za Zhi; 1998 Dec; 33(12):731-4. PubMed ID: 10806662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
